SMTI
Sanara MedTech Inc.
Price Chart
Latest Quote
$22.02
+0.80 (+3.77%)
Current Price
| Previous Close | $21.22 |
| Open | $21.82 |
| Day High | $22.48 |
| Day Low | $20.81 |
| Volume | 132,300 |
Stock Information
| Shares Outstanding | 9.16M |
| Total Debt | $48.37M |
| Cash Equivalents | $13.59M |
| Revenue | $107.48M |
| Net Income | $631K |
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Market Cap | $201.79M |
| P/E Ratio | 367.00 |
| EPS (TTM) | $0.06 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $242.69M |
| Sales | $107.48M |
| Income | $631K |
| Book/sh | $0.77 |
| Cash/sh | $1.48 |
| Employees | 108 |
Financial Ratios
| Quick Ratio | 1.99 |
| Current Ratio | 2.28 |
| Debt/Eq | 689.01 |
Returns & Margins
| ROA | 8.27% |
| ROE | 2.86% |
| Gross Margin | 92.92% |
| Operating Margin | 9.52% |
| Profit Margin | -31.24% |
Ownership
| Insider Ownership | 53.70% |
| Institutional Ownership | 16.53% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 40.78 |
| P/S | 1.88 |
| P/B | 28.71 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $34.33 |
Technical Indicators
| SMA20 | $22.32 |
| SMA50 | $20.70 |
| SMA200 | $23.50 |
| RSI | 46.46 |
| ATR | 1.4400 |
| Shares Float | 3.74M |
| Short Float | 5.11% |
| Short Ratio | 5.81 |
| Volatility | 1.19 |
| Rel Volume | 2.41 |
Performance History
| Week | +2.42% |
| Month | -3.08% |
| Quarter | +17.63% |
| 6 Months | -12.62% |
| YTD | -4.68% |
| Year | -20.85% |
| 3 Years | -44.24% |
| 5 Years | -26.35% |
| 10 Years | +214.57% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-18 | $22.02 | 133,600 |
| 2026-06-17 | $21.22 | 122,600 |
| 2026-06-16 | $22.69 | 60,000 |
| 2026-06-15 | $21.89 | 64,800 |
| 2026-06-12 | $20.81 | 48,900 |
| 2026-06-11 | $21.50 | 70,000 |
| 2026-06-10 | $22.99 | 81,400 |
| 2026-06-09 | $22.72 | 80,500 |
| 2026-06-08 | $22.09 | 46,100 |
| 2026-06-05 | $22.44 | 40,000 |
| 2026-06-04 | $22.12 | 35,100 |
| 2026-06-03 | $20.97 | 49,000 |
| 2026-06-02 | $21.26 | 36,500 |
| 2026-06-01 | $21.92 | 42,300 |
| 2026-05-29 | $22.79 | 28,100 |
| 2026-05-28 | $23.79 | 32,700 |
| 2026-05-27 | $23.38 | 23,200 |
| 2026-05-26 | $22.93 | 28,300 |
| 2026-05-22 | $23.17 | 45,400 |
| 2026-05-21 | $23.64 | 40,900 |
| 2026-05-20 | $23.00 | 33,300 |
| 2026-05-19 | $22.72 | 31,900 |
About Sanara MedTech Inc.
Sanara MedTech Inc., a medical technology company, develops, markets, and distributes surgical solutions to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns. It also develops BIASURGE, a no-rinse surgical solution used for wound irrigation; FORTIFY Tissue Repair Graft(FORTIFY TRG), a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; BiFORM, an osteoconductive, bioactive, porous implant that allows bony ingrowth across the graft site and it can be used as a strip or molded into a putty to fill a bone defect; ACTIGEN Inductive Bone Matrix, a naturally derived, differentiated allograft matrix with robust handling properties; ALLOCYTE Plus, a human allograft cellular bone matrix containing bone-derived progenitor cells and conformable bone fibers; and TEXAGEN, a multi-layer amniotic membrane allograft used as an anatomical barrier with robust handling that can be sutured for securement. The company has a license agreement with Rochal to develop, market, and sell antimicrobial products that include BIASURGE Advanced Surgical Solution, BIAKOS Antimicrobial Wound Gel, and BIAKOS Antimicrobial Skin and Wound Cleanser for the prevention and treatment of microbes on the human body. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.
đ° Latest News
Sanara MedTech (SMTI) Q1 2026 Earnings Transcript
Motley Fool âĸ 2026-06-02T16:56:58Z
How The Sanara MedTech (SMTI) Narrative Is Shifting As The US$34 Target Stays Put
Simply Wall St. âĸ 2026-05-23T01:14:51Z
Sanara MedTech Inc. Q1 2026 Earnings Call Summary
Moby âĸ 2026-05-13T12:30:00Z
Sanara MedTech Inc (SMTI) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
GuruFocus.com âĸ 2026-05-12T19:02:42ZICU Medical (ICUI) Tops Q1 Earnings and Revenue Estimates
Zacks âĸ 2026-05-07T23:05:20Z
Insulet (PODD) Q1 Earnings and Revenues Top Estimates
Zacks âĸ 2026-05-06T12:25:07Z
How Sanara MedTech (SMTI) Is Reframing Its Growth Story Around A Steady US$34 Target
Simply Wall St. âĸ 2026-05-05T13:17:21Z
Sanara MedTech (SMTI) Q4 2025 Earnings Transcript
Motley Fool âĸ 2026-05-04T16:53:44Z
What Makes Sanara Medtech (SMTI) A Compelling Risk-Reward Opportunity?
Insider Monkey âĸ 2026-04-23T13:20:23Z
How The Sanara MedTech (SMTI) Story Is Shifting With New Targets And Growth Assumptions
Simply Wall St. âĸ 2026-04-20T15:06:21Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $6,236,877 | $6,002,506 | $7,852,686 | $6,360,851 |
| Cost Of Revenue | $7,520,969 | $8,139,901 | $7,852,686 | $6,360,851 |
| Total Revenue | $103,117,982 | $86,672,425 | $64,989,842 | $45,842,845 |
| Operating Revenue | $103,117,982 | $86,672,425 | $64,989,842 | $45,842,845 |
| Expenses | ||||
| Interest Expense | $6,759,800 | $3,128,395 | $475,783 | $0 |
| Total Expenses | $93,972,324 | $85,428,035 | $72,654,890 | $58,075,279 |
| Other Income Expense | $-2,782,654 | $-75,556 | $3,700,929 | $-1,704,690 |
| Net Non Operating Interest Income Expense | $-6,756,128 | $-3,106,417 | $-475,783 | $0 |
| Interest Expense Non Operating | $6,759,800 | $3,128,395 | $475,783 | $0 |
| Operating Expense | $86,451,355 | $77,288,134 | $64,802,204 | $51,714,428 |
| General And Administrative Expense | - | - | - | $45,976,328 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-387,683 | $-1,690,232 | $-4,303,197 | $-7,937,497 |
| Net Interest Income | $-6,756,128 | $-3,106,417 | $-475,783 | $0 |
| Interest Income | $3,672 | $21,978 | $0 | - |
| Normalized Income | $1,442,505 | $-1,704,683 | $-8,004,126 | $-6,890,702 |
| Net Income From Continuing And Discontinued Operation | $-37,562,606 | $-9,664,547 | $-4,303,197 | $-7,937,497 |
| Total Operating Income As Reported | $7,304,538 | $1,258,841 | $-4,215,153 | $-12,517,180 |
| Net Income Common Stockholders | $-37,562,606 | $-9,664,547 | $-4,303,197 | $-7,937,497 |
| Net Income | $-37,562,606 | $-9,664,547 | $-4,303,197 | $-7,937,497 |
| Net Income Including Noncontrolling Interests | $-37,568,047 | $-9,911,898 | $-4,439,902 | $-8,092,328 |
| Net Income Discontinuous Operations | $-37,174,923 | $-7,974,315 | - | - |
| Net Income Continuous Operations | $-393,124 | $-1,937,583 | $-4,439,902 | $-8,092,328 |
| Pretax Income | $-393,124 | $-1,937,583 | $-4,439,902 | $-13,937,124 |
| Special Income Charges | $-1,830,188 | $14,451 | $3,449,895 | $-284,746 |
| Earnings From Equity Interest | $-952,466 | $-90,007 | $0 | $-379,633 |
| Interest Income Non Operating | $3,672 | $21,978 | $0 | - |
| Operating Income | $9,145,658 | $1,244,390 | $-7,665,048 | $-12,232,434 |
| Depreciation Amortization Depletion Income Statement | $2,661,873 | $2,785,829 | $3,675,026 | $2,371,068 |
| Depreciation And Amortization In Income Statement | $2,661,873 | $2,785,829 | $3,675,026 | $2,371,068 |
| Gross Profit | $95,597,013 | $78,532,524 | $57,137,156 | $39,481,994 |
| Per Share | ||||
| Diluted EPS | $-4.36 | $-1.14 | $-0.52 | $-1.00 |
| Basic EPS | $-4.36 | $-1.14 | $-0.52 | $-1.00 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $0 | $-278,262 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $12,142,829 | $6,099,585 | $-3,990,022 | $-10,240,999 |
| Total Unusual Items | $-1,830,188 | $14,451 | $3,700,929 | $-1,325,057 |
| Total Unusual Items Excluding Goodwill | $-1,830,188 | $14,451 | $3,700,929 | $-1,325,057 |
| Reconciled Depreciation | $3,945,965 | $4,923,224 | $3,675,026 | $2,371,068 |
| EBITDA (Bullshit earnings) | $10,312,641 | $6,114,036 | $-289,093 | $-11,566,056 |
| EBIT | $6,366,676 | $1,190,812 | $-3,964,119 | $-13,937,124 |
| Diluted Average Shares | $8,623,028 | $8,484,224 | $8,278,949 | $7,906,794 |
| Basic Average Shares | $8,623,028 | $8,484,224 | $8,278,949 | $7,906,794 |
| Diluted NI Availto Com Stockholders | $-37,562,606 | $-9,664,547 | $-4,303,197 | $-7,937,497 |
| Minority Interests | $5,441 | $247,351 | $136,705 | $154,831 |
| Gain On Sale Of Ppe | $10,932 | $0 | - | - |
| Impairment Of Capital Assets | $1,841,120 | $0 | - | - |
| Restructuring And Mergern Acquisition | $0 | $-14,451 | $-3,449,895 | $284,746 |
| Research And Development | $5,072,483 | $2,828,663 | $4,132,425 | $3,367,032 |
| Selling General And Administration | $78,716,999 | $71,673,642 | $56,994,753 | $45,976,328 |
| Tax Provision | - | - | $0 | $-5,844,796 |
| Gain On Sale Of Security | - | - | $251,034 | $-1,040,311 |
| Other Gand A | - | - | - | $45,976,328 |
Fetched: 2026-06-14
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-16,304,012 | $12,320,697 | $-3,695,565 | $6,715,769 |
| Total Assets | $72,944,071 | $88,091,992 | $73,871,149 | $61,035,386 |
| Total Non Current Assets | $39,401,908 | $54,786,004 | $54,865,280 | $40,418,877 |
| Goodwill And Other Intangible Assets | $22,242,454 | $27,082,876 | $48,527,842 | $35,111,761 |
| Other Intangible Assets | $18,640,673 | $23,481,095 | $44,926,061 | $31,509,980 |
| Current Assets | $33,542,163 | $33,305,988 | $19,005,869 | $20,616,509 |
| Other Current Assets | $948,620 | $1,022,464 | $608,411 | $1,104,611 |
| Assets Held For Sale Current | $67,863 | $101,334 | - | - |
| Inventory | $3,948,748 | $2,753,032 | $4,717,533 | $3,549,000 |
| Receivables | $11,998,075 | $13,550,863 | $8,532,709 | $7,003,903 |
| Loans Receivable | $0 | $1,101,478 | $0 | - |
| Accounts Receivable | $11,998,075 | $12,408,819 | $8,474,965 | $6,805,761 |
| Allowance For Doubtful Accounts Receivable | $-1,372,000 | $-1,173,441 | $-528,030 | $-325,089 |
| Gross Accounts Receivable | $13,370,075 | $13,582,260 | $9,002,995 | $7,130,850 |
| Cash Cash Equivalents And Short Term Investments | $16,578,857 | $15,878,295 | $5,147,216 | $8,958,995 |
| Cash And Cash Equivalents | $16,578,857 | $15,878,295 | $5,147,216 | $8,958,995 |
| Cash Financial | $16,578,857 | $15,878,295 | $5,147,216 | $8,958,995 |
| Other Non Current Assets | - | $19,609,959 | - | - |
| Other Receivables | - | - | $49,344 | $99,594 |
| Prepaid Assets | - | - | - | - |
| Debt | ||||
| Net Debt | $29,392,080 | $14,810,995 | $4,546,264 | - |
| Total Debt | $48,192,869 | $32,285,028 | $11,792,110 | $819,224 |
| Long Term Debt And Capital Lease Obligation | $47,839,640 | $31,926,341 | $10,850,568 | $505,291 |
| Long Term Debt | $45,970,937 | $30,689,290 | $9,113,123 | - |
| Current Debt And Capital Lease Obligation | $353,229 | $358,687 | $941,542 | $313,933 |
| Current Debt | - | - | $580,357 | - |
| Other Current Borrowings | - | - | $580,357 | - |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $67,014,295 | $49,180,030 | $29,283,132 | $19,315,411 |
| Total Non Current Liabilities Net Minority Interest | $48,387,765 | $33,889,959 | $15,515,255 | $6,509,102 |
| Other Non Current Liabilities | $548,125 | $1,963,618 | $4,664,687 | $6,003,811 |
| Current Liabilities | $18,626,530 | $15,290,071 | $13,767,877 | $12,806,309 |
| Other Current Liabilities | $1,468,479 | $1,050,820 | $1,100,000 | $1,162,880 |
| Payables And Accrued Expenses | $5,023,387 | $3,795,914 | $4,049,565 | $3,571,212 |
| Payables | $2,338,761 | $1,530,677 | $2,001,887 | $1,426,737 |
| Accounts Payable | $2,338,761 | $1,530,677 | $2,001,887 | $1,426,737 |
| Equity | ||||
| Common Stock Equity | $5,938,442 | $39,403,573 | $44,832,277 | $41,827,530 |
| Total Equity Gross Minority Interest | $5,929,776 | $38,911,962 | $44,588,017 | $41,719,975 |
| Stockholders Equity | $5,938,442 | $39,403,573 | $44,832,277 | $41,827,530 |
| Retained Earnings | $-75,303,042 | $-37,784,392 | $-28,036,814 | $-23,394,757 |
| Other | ||||
| Ordinary Shares Number | $8,946,913 | $8,753,773 | $8,535,239 | $8,299,957 |
| Share Issued | $8,946,913 | $8,753,773 | $8,535,239 | $8,299,957 |
| Tangible Book Value | $-16,304,012 | $12,320,697 | $-3,695,565 | $6,715,769 |
| Invested Capital | $51,909,379 | $70,092,863 | $54,525,757 | $41,827,530 |
| Working Capital | $14,915,633 | $18,015,917 | $5,237,992 | $7,810,200 |
| Capital Lease Obligations | $2,221,932 | $1,595,738 | $2,098,630 | $819,224 |
| Total Capitalization | $51,909,379 | $70,092,863 | $53,945,400 | $41,827,530 |
| Minority Interest | $-8,666 | $-491,611 | $-244,260 | $-107,555 |
| Additional Paid In Capital | $81,232,536 | $77,179,211 | $72,860,556 | $65,213,987 |
| Capital Stock | $8,948 | $8,754 | $8,535 | $8,300 |
| Common Stock | $8,948 | $8,754 | $8,535 | $8,300 |
| Long Term Capital Lease Obligation | $1,868,703 | $1,237,051 | $1,737,445 | $505,291 |
| Current Capital Lease Obligation | $353,229 | $358,687 | $361,185 | $313,933 |
| Pensionand Other Post Retirement Benefit Plans Current | $11,781,435 | $10,084,650 | $7,676,770 | $7,758,284 |
| Current Accrued Expenses | $2,684,626 | $2,265,237 | $2,047,678 | $2,144,475 |
| Investments And Advances | $14,626,858 | $6,212,945 | $3,084,278 | $3,084,278 |
| Goodwill | $3,601,781 | $3,601,781 | $3,601,781 | $3,601,781 |
| Net PPE | $2,532,596 | $1,880,224 | $3,253,160 | $2,222,838 |
| Accumulated Depreciation | $-672,872 | $-608,613 | $-1,196,124 | $-739,986 |
| Gross PPE | $3,205,468 | $2,488,837 | $4,449,284 | $2,962,824 |
| Leases | $231,022 | $181,968 | $134,170 | $19,631 |
| Other Properties | $2,075,634 | $1,447,907 | $1,995,204 | $806,402 |
| Machinery Furniture Equipment | $898,812 | $858,962 | $2,319,910 | $2,136,791 |
| Properties | $0 | $0 | $0 | $0 |
| Inventories Adjustments Allowances | $-623,835 | $-534,549 | $-446,917 | $-523,832 |
| Other Inventories | $4,572,583 | $3,287,581 | $5,164,450 | $4,072,832 |
| Duefrom Related Parties Current | $0 | $40,566 | $8,400 | $98,548 |
| Dueto Related Parties Current | - | $30,913 | $77,805 | $34,036 |
Fetched: 2026-06-14
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $2,137,527 | $-253,084 | $-3,510,802 | $-6,301,885 |
| Operating Activities | ||||
| Operating Cash Flow | $6,786,629 | $-23,784 | $-3,245,556 | $-5,554,870 |
| Cash Flow From Continuing Operating Activities | $6,786,629 | $-23,784 | $-3,245,556 | $-5,554,870 |
| Operating Gains Losses | $942,792 | $90,007 | $-251,034 | $1,422,578 |
| Investing Activities | ||||
| Capital Expenditure | $-4,649,102 | $-229,300 | $-265,246 | $-747,015 |
| Investing Cash Flow | $-14,973,890 | $-6,611,643 | $-10,207,346 | $-3,511,630 |
| Cash Flow From Continuing Investing Activities | $-14,973,890 | $-6,611,643 | $-10,207,346 | $-3,511,630 |
| Net Other Investing Changes | - | $-1,079,391 | - | $1,549 |
| Financing Activities | ||||
| Financing Cash Flow | $8,887,823 | $17,366,506 | $9,641,123 | $-627,346 |
| Cash Flow From Continuing Financing Activities | $8,887,823 | $17,366,506 | $9,641,123 | $-627,346 |
| Net Other Financing Charges | $-937,000 | $-2,022,549 | $-822,795 | $-220,000 |
| Net Common Stock Issuance | $0 | $-75,000 | $911,371 | $0 |
| Issuance Of Capital Stock | - | - | $911,371 | $0 |
| Common Stock Issuance | - | - | $911,371 | $0 |
| Other | ||||
| Repayment Of Debt | $-1,650,000 | $-9,750,000 | $0 | $0 |
| Issuance Of Debt | $12,021,817 | $29,339,260 | $9,688,341 | $0 |
| Interest Paid Supplemental Data | $3,351,791 | $1,580,984 | $283,948 | $206 |
| End Cash Position | $16,578,857 | $15,878,295 | $5,147,216 | $8,958,995 |
| Beginning Cash Position | $15,878,295 | $5,147,216 | $8,958,995 | $18,652,841 |
| Changes In Cash | $700,562 | $10,731,079 | $-3,811,779 | $-9,693,846 |
| Proceeds From Stock Option Exercised | $-546,994 | $-125,205 | $-135,794 | $-407,346 |
| Net Issuance Payments Of Debt | $10,371,817 | $19,589,260 | $9,688,341 | $0 |
| Net Long Term Debt Issuance | $10,371,817 | $19,589,260 | $9,688,341 | $0 |
| Long Term Debt Payments | $-1,650,000 | $-9,750,000 | $0 | - |
| Long Term Debt Issuance | $12,021,817 | $29,339,260 | $9,688,341 | $0 |
| Net Investment Purchase And Sale | $-8,262,642 | $-5,302,952 | $0 | $-250,000 |
| Purchase Of Investment | $-8,262,642 | $-5,302,952 | $0 | $-250,000 |
| Net Business Purchase And Sale | $-2,122,146 | $0 | $-9,942,750 | $-2,516,164 |
| Purchase Of Business | $-2,122,146 | $0 | $-9,942,750 | $-2,516,164 |
| Net Intangibles Purchase And Sale | $-23,452 | $-23,452 | $0 | $-600,000 |
| Purchase Of Intangibles | $-23,452 | $-23,452 | $0 | $-600,000 |
| Net PPE Purchase And Sale | $-4,565,650 | $-205,848 | $-264,596 | $-145,466 |
| Sale Of PPE | $60,000 | $0 | $650 | $1,549 |
| Purchase Of PPE | $-4,625,650 | $-205,848 | $-265,246 | $-147,015 |
| Change In Working Capital | $972,971 | $-911,719 | $-3,279,262 | $517,621 |
| Change In Other Current Liabilities | $-526,905 | $-502,892 | $-252,366 | $-263,370 |
| Change In Payables And Accrued Expense | $3,228,247 | $3,205,049 | $-246,010 | $3,726,838 |
| Change In Accrued Expense | $2,420,161 | $3,676,258 | $-821,158 | $4,150,585 |
| Change In Payable | $808,086 | $-471,209 | $575,148 | $-423,747 |
| Change In Account Payable | $808,086 | $-471,209 | $575,148 | $-423,747 |
| Change In Prepaid Assets | $123,515 | $-515,496 | $496,200 | $-159,592 |
| Change In Inventory | $-1,777,762 | $1,442,744 | $-1,545,339 | $-517,271 |
| Change In Receivables | $-74,124 | $-4,541,124 | $-1,731,747 | $-2,268,984 |
| Changes In Account Receivables | $-74,124 | $-4,541,124 | $-1,731,747 | $-2,268,984 |
| Other Non Cash Items | $4,515,427 | $726,106 | $-2,596,047 | $1,088,354 |
| Stock Based Compensation | $5,154,761 | $4,436,048 | $3,442,722 | $2,702,633 |
| Asset Impairment Charge | $28,822,760 | $624,448 | $202,941 | $280,000 |
| Depreciation Amortization Depletion | $3,945,965 | $4,923,224 | $3,675,026 | $2,371,068 |
| Depreciation And Amortization | $3,945,965 | $4,923,224 | $3,675,026 | $2,371,068 |
| Earnings Losses From Equity Investments | $952,466 | $90,007 | $0 | $379,633 |
| Gain Loss On Sale Of PPE | $-9,674 | $0 | $0 | $2,634 |
| Net Income From Continuing Operations | $-37,568,047 | $-9,911,898 | $-4,439,902 | $-8,092,328 |
| Amortization Cash Flow | - | $3,891,737 | $3,218,888 | $1,963,299 |
| Amortization Of Intangibles | - | $3,891,737 | $3,218,888 | $1,963,299 |
| Depreciation | - | $1,031,487 | $456,138 | $407,769 |
| Deferred Tax | - | - | $0 | $-5,844,796 |
| Deferred Income Tax | - | - | $0 | $-5,844,796 |
| Gain Loss On Investment Securities | - | - | $-251,034 | $1,040,311 |
| Net Short Term Debt Issuance | - | - | - | $0 |
| Short Term Debt Payments | - | - | - | $0 |
| Short Term Debt Issuance | - | - | - | $0 |
| Income Tax Paid Supplemental Data | - | - | - | - |
Fetched: 2026-06-14